Terrance Gregg, a special venture partner with Galen Associates, has been named president and CEO of Vasogen Inc. (Nasdaq: VSGN), an Ontario-based biotech company focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. www.vasogen.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.